References
gastrointestinal symptoms, fat-free mass
ADVERSE EVENT, EVENTS
Summary of the study design.Flow diagram of the study progress through the different phases (according to CONSORT).Alteration in body fat mass (∆ BFM) (kg) (primary parameter) during intervention, as assessed with bioimpedance (BIA). Means ± SEMs. * Composition of the test products.a.p.: at production; a.e.s.: target colony-forming units (CFU) at the end of shelf-life.Baseline characteristics of the FAS population (a: Baseline characteristics of the FAS population (Alteration (∆V3-V1) in body composition during intervention in the FAS, as assessed with body impedance analysis (BIA): absolute (abs) (kg) and relative (rel) (%) body fat mass (BFM); fat-free mass (FFM) (kg); visceral adipose tissue (VATAlterations (∆V3-V1) in anthropometric data and blood pressure during intervention. Comparison among Probiotic (Pro), Synbiotic (Syn) and Placebo groups (Pla). Alterations (∆V3-V1) in laboratory parameters during intervention. Comparison among Probiotic (Pro), Synbiotic (Syn) and Placebo groups (Pla). Alterations (∆V3-V1) in visceral adipose tissue (VATAlterations (∆V3-V1) in gastrointestinal symptoms during intervention, as assessed with the Gastrointestinal Score Rating Scale (GSRS) [Adverse events (AEs) during intervention (occurrence = number of individuals who experienced one or more AEs; incidence = number of events). Comparison among Probiotic (Pro), Synbiotic (Syn) and Placebo groups (Pla). *—chi-square-inaccurate.